A number of potential biomarkers of response to immunotherapy in sarcoma have been investigated including microsatellite instability (MSI), mismatch repair deficiency (dMMR), tumour mutation burden (TMB), PD-L1 expression, infiltration of TILs, B cell-related gene signature and presence of intratumoral tertiary lymphoid structures (TLSs) (137, 138). This evidence concerns the gene CD274 and sarcoma.